Dopamine

Dopamine (DA, chemically 3,4-dihydroxyphenethylamine or 4-(2-aminoethyl)benzene-1,2-diol; formula C₈H₁₁NO₂, molar mass 153.18 g mol⁻¹) is an endogenous catecholamine neurotransmitter and neurohormone that mediates slow metabotropic neuromodulation across the vertebrate and invertebrate nervous system and serves as the direct biosynthetic precursor to norepinephrine (noradrenaline) and epinephrine (adrenaline). Although dopaminergic neurons account for fewer than 1% of the ~86 billion neurons in the adult human brain (~400,000–600,000 cell bodies concentrated in the ventral midbrain), their expansive axonal arbors project throughout the striatum, prefrontal cortex, limbic system, and hypothalamus to govern four foundational physiological processes: voluntary motor initiation, reward-prediction-error (RPE) reinforcement learning and motivational salience, working memory and executive attention, and tonic inhibition of anterior pituitary prolactin release.

First synthesized chemically in 1910 by George Barger and James Ewens and identified as an independent central neurotransmitter (rather than merely a norepinephrine intermediate) by Arvid Carlsson and colleagues in 1957–1958 (work awarded the 2000 Nobel Prize in Physiology or Medicine), dysregulation of central dopaminergic signaling underlies major neurological and psychiatric disorders—including the nigrostriatal degeneration of Parkinson's disease, mesolimbic and mesocortical dysfunctions in schizophrenia, attention-deficit/hyperactivity disorder (ADHD), and substance-use addiction.

The Rate-Limiting Tyrosine Hydroxylase Pathway

Because circulating peripheral dopamine is protonated at physiological pH (amine p*K*_a ≈ 8.9) and cannot cross the blood–brain barrier, central nervous system neurons synthesize dopamine de novo in presynaptic cytosol from the aromatic amino acid L-tyrosine (which enters the brain via the large neutral amino acid transporter LAT1 / SLC7A5) in a two-step enzymatic cascade:

1. L-Tyrosine → L-DOPA (Rate-Limiting Step): The non-heme iron-dependent monooxygenase tyrosine hydroxylase (TH, EC 1.14.16.2) catalyzes the meta-hydroxylation of L-tyrosine using molecular oxygen (O₂) and the cofactor tetrahydrobiopterin (BH₄) to yield L-3,4-dihydroxyphenylalanine (L-DOPA, levodopa). Tyrosine hydroxylase activity is tightly regulated by short-term feedback inhibition from cytosolic catecholamines competing with BH₄ at the Fe²⁺ active site and by activating phosphorylation of regulatory N-terminal serine residues (Ser19, Ser31, Ser40) via PKA, CaMKII, and ERK.
2. L-DOPA → Dopamine: Cytosolic aromatic L-amino acid decarboxylase (AADC / DOPA decarboxylase, EC 4.1.1.28), utilizing pyridoxal 5'-phosphate (PLP, active vitamin B₆) as a Schiff-base cofactor, rapidly decarboxylates L-DOPA to produce dopamine and CO₂. Because AADC has high catalytic turnover and L-DOPA crosses the blood–brain barrier via LAT1, oral administration of L-DOPA paired with a peripheral decarboxylase inhibitor (carbidopa or benserazide) restores striatal dopamine synthesis in Parkinson's disease.

VMAT2 Sequestration, DAT Reuptake, and COMT/MAO Degradation

Once synthesized in the axoplasm, dopamine is rapidly pumped into synaptic vesicles by the vesicular monoamine transporter 2 (VMAT2 / SLC18A2), an H⁺-antiporter that exchanges two luminal protons (established by a V-type H⁺-ATPase) for one cytoplasmic monoamine cation, concentrating intravesicular dopamine to ~0.1–0.5 M and protecting it from cytosolic autoxidation into neurotoxic o-quinones. Upon action-potential arrival and voltage-gated Ca²⁺ influx, SNARE-mediated vesicular exocytosis releases dopamine into the synaptic cleft and extrasynaptic space (volume transmission).

Signaling is terminated by the dopamine transporter (DAT / SLC6A3), a 12-transmembrane Na⁺/Cl⁻-coupled symporter on the presynaptic membrane that co-transports 1 DA⁺ with 2 Na⁺ and 1 Cl⁻ back into the terminal (the primary molecular target inhibited by cocaine and methylphenidate, and reversed by amphetamines). Intracellular and extracellular dopamine is catabolized into homovanillic acid (HVA)—the principal urinary and cerebrospinal fluid biomarker of central dopamine turnover—by the sequential action of two enzymes encoded on loci profiled in BDNF, COMT, and DRD2 neurogenetics:

• Monoamine Oxidase (MAO-A and MAO-B): Outer-mitochondrial-membrane flavoproteins that oxidatively deaminate dopamine to 3,4-dihydroxyphenylacetaldehyde (DOPAL), which aldehyde dehydrogenase (ALDH) oxidizes to 3,4-dihydroxyphenylacetic acid (DOPAC).
• Catechol-O-Methyltransferase (COMT): Transfers a methyl group from S-adenosylmethionine (SAM) to the 3-hydroxyl group of dopamine (yielding 3-methoxytyramine) or DOPAC, producing homovanillic acid (HVA). In the prefrontal cortex—where DAT expression is sparse—COMT (and its Val158Met polymorphism) accounts for over half of extracellular dopamine clearance.

Dopamine exerts its physiological effects exclusively through five class A rhodopsin-like G-protein-coupled receptors (D₁ to D₅), divided on structural, pharmacological, and second-messenger grounds into two opposing subfamilies:

In striatal medium spiny neurons, D₁ activation stimulates cyclic AMP-dependent protein kinase A (PKA) to phosphorylate DARPP-32 at Thr34, converting DARPP-32 into a potent inhibitor of protein phosphatase-1 (PP-1, IC₅₀ ≈ 1 nM) and amplifying AMPA/NMDA receptor phosphorylation (work elucidated by Paul Greengard). Conversely, D₂ receptor activation lowers cAMP and stimulates calcineurin (PP-2B) to dephosphorylate Thr34, opposing D₁ signaling.

1. Nigrostriatal Pathway (Substantia Nigra Pars Compacta, A9 → Dorsal Striatum): Contains ~75% of brain dopamine. Excites D₁-expressing direct-pathway striatonigral neurons while inhibiting D₂-expressing indirect-pathway striatopallidal neurons, releasing tonic pallidal inhibition of the motor thalamus to initiate smooth voluntary movement. Loss of >60–80% of A9 neuromelanin-pigmented neurons (often linked to SNCA α-synuclein Lewy bodies or LRRK2 / GBA1 variants) produces the resting tremor, cogwheel rigidity, and bradykinesia of Parkinson's disease.
2. Mesolimbic Pathway (Ventral Tegmental Area, A10 → Nucleus Accumbens, Amygdala, Hippocampus): Mediates incentive salience ("wanting") and reinforcement learning. As demonstrated in seminal electrophysiology recordings by Wolfram Schultz, Peter Dayan, and Read Montague (1997), VTA dopamine neurons fire at a tonic baseline of ~4–5 Hz, burst at 20–40 Hz when an animal receives an unexpected reward (or a conditioned cue predicting reward), remain unchanged when a fully predicted reward arrives, and pause below baseline when an expected reward is omitted—computing the exact mathematical temporal-difference reward prediction error (δ_t):

1. Mesocortical Pathway (VTA, A10 → Prefrontal Cortex): Regulates dorsolateral prefrontal working memory, cognitive flexibility, and emotional regulation following an inverted-U dose-response curve, where either excessive or deficient D₁ stimulation degrades signal-to-noise firing of delay-period pyramidal cells.
2. Tuberoinfundibular Pathway (Arcuate Nucleus of Hypothalamus, A12 → Median Eminence / Portal Vessels): Releases dopamine into the hypophyseal portal circulation to bind D₂ receptors on anterior pituitary lactotrophs, providing tonic physiological inhibition of prolactin secretion (explaining why D₂-blocking antipsychotics such as risperidone or haloperidol cause hyperprolactinemia).

Is dopamine the brain's "pleasure molecule"?

Not strictly. Contemporary affective neuroscience (notably the work of Kent Berridge and Terry Robinson) distinguishes between "liking" (the hedonic pleasure of consuming a reward, mediated primarily by endogenous opioid and endocannabinoid "hedonic hotspots" in the nucleus accumbens shell and ventral pallidum) and "wanting" (motivational incentive salience and reward-prediction-error learning, mediated by mesolimbic dopamine). Depleting striatal dopamine leaves hedonic facial pleasure reactions to sweet sucrose intact, but abolishes the animal's motivational drive to work for or seek out the reward.

Why are Parkinson's disease patients treated with L-DOPA plus carbidopa instead of dopamine directly?

Dopamine is a polar catecholamine that cannot cross the tight endothelial junctions of the blood–brain barrier, and intravenous dopamine acts only on peripheral cardiovascular and renal receptors (used clinically as an ICU vasopressor/inotrope). Its amino-acid precursor L-DOPA is actively transported across the blood–brain barrier by the neutral amino acid carrier LAT1. Co-administering carbidopa—a peripheral DOPA decarboxylase inhibitor that cannot cross the blood–brain barrier—prevents 90% of oral L-DOPA from being prematurely converted into dopamine in the gut and bloodstream, eliminating severe nausea and cardiac arrhythmias while quadrupling L-DOPA delivery into the striatum.

How do stimulant medications for ADHD increase focus if they raise dopamine and norepinephrine?

In the prefrontal cortex, attentional control and working memory follow an inverted-U (Yerkes–Dodson) relationship with catecholamine tone. At low baseline catecholamine levels, prefrontal pyramidal networks exhibit noisy, distractible firing. Low-to-moderate oral therapeutic doses of methylphenidate or amphetamine preferentially elevate tonic extracellular norepinephrine (acting on high-affinity postsynaptic α_2A-adrenergic receptors to strengthen network connectivity) and dopamine (acting on D₁ receptors to suppress non-preferred background noise), shifting prefrontal circuitry up to the peak of the inverted-U curve without triggering the high-amplitude striatal phasic surges associated with intravenous abuse.

1. Carlsson, A., Lindqvist, M., & Magnusson, T. (1957). "3,4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists." Nature, 180(4596), 1200. https://doi.org/10.1038/1801200a0
2. Schultz, W., Dayan, P., & Montague, P. R. (1997). "A neural substrate of prediction and reward." Science, 275(5306), 1593–1599. https://doi.org/10.1126/science.275.5306.1593
3. Beaulieu, J.-M., & Gainetdinov, R. R. (2011). "The physiology, signaling, and pharmacology of dopamine receptors." Pharmacological Reviews, 63(1), 182–217. https://doi.org/10.1124/pr.110.002642
4. Berridge, K. C., & Robinson, T. E. (2016). "Liking, wanting, and the incentive-sensitization theory of addiction." American Psychologist, 71(8), 670–679. https://doi.org/10.1037/amp0000059